The novel glucagon receptor agonist SAR438544, first in human safety, pharmacokinetic and pharmacodynamic data from a study in healthy volunteers

Publication Authors:

Hompesch, M; Grosjean, P; Morrow, L; Hijazi, Y; Ishibai, M; Teichert, L; Bergmann, K

Poster presented at 53rd European Association for the Study of Diabetes (EASD) Annual Meeting, Lisbon, Portugal, September 2017.

About

About this Poster:

SAR438544 is a novel synthetic agonist of the glucagon receptor in a stable formulation for subcutaneous (SC) injection to treat hypoglycemia. A first-in-human, randomized, double-blind, glucagon and placebo-controlled, single ascending dose study to evaluate safety, tolerability, PK and PD of SAR438544 was conducted in healthy volunteers.

VIEW
The novel glucagon receptor agonist SAR438544, first in human safety, pharmacokinetic and pharmacodynamic data from a study in healthy volunteers thumbnail